Alkermes ALKS
NASDAQ ALKS
$45.40 -0.09 (-0.20%)
As of: Sep 9, 2026 · 3:59 PM EDT

Alkermes (ALKS) Change in Accured Expenses (2010 - 2026)

Alkermes' (ALKS) quarterly Change in Accured Expenses came in at $41.2 million in Q2 2026, down 22.67% year-over-year from $53.3 million in Q2 2025, and up 134.47% quarter-over-quarter from -$119.5 million in Q1 2026.

Analysis

Alkermes (ALKS) Change in Accured Expenses (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Change in Accured Expenses for 17 consecutive years, with $41.2 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Change in Accured Expenses fell 22.67% year-over-year to $41.2 million in Q2 2026; TTM through Jun 2026 was -$33.5 million, a 46630.56% decrease from a year earlier, with the FY2025 full-year figure at $100.9 million, up 274.05% from the prior year.
  • Change in Accured Expenses was $41.2 million for Q2 2026 at Alkermes, up from -$119.5 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $73.0 million in Q4 2025 and troughed at -$119.5 million in Q1 2026.
  • A 5-year average of $176833.3 and a median of $3.0 million in 2022 frame the typical range for Change in Accured Expenses.
  • The widest YoY moves for Change in Accured Expenses: up 1119.45% in 2024, down 8516.2% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $3.1 million in 2022, then sank by 34.05% to $2.1 million in 2023, then surged by 1119.45% to $25.0 million in 2024, then surged by 191.99% to $73.0 million in 2025, then plunged by 43.6% to $41.2 million in 2026.
  • The last three Change in Accured Expenses figures came in at $41.2 million (Q2 2026), -$119.5 million (Q1 2026), and $73.0 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Johnson & Johnson 643.26 Bn 622.50 Bn 17.26 Bn 2.32 Bn
2 AbbVie 443.31 Bn 436.74 Bn 12.70 Bn 1.20 Bn
3 Merck 364.74 Bn 357.60 Bn 12.21 Bn -
4 Novartis Ag 266.46 Bn 258.77 Bn 11.24 Bn -
5 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn -
6 Sanofi 52.33 Bn 44.95 Bn 10.79 Bn -
7 Revolution Medicines 43.79 Bn 43.79 Bn - 55.78 Mn
8 Incyte 25.23 Bn 20.69 Bn 1.57 Bn -204.33 Mn
9 United Therapeutics 21.67 Bn 19.01 Bn 683.80 Mn -4.00 Mn
10 Alkermes 7.58 Bn 6.92 Bn 397.90 Mn 41.19 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 41.19 Mn
Mar 31, 2026 -119.47 Mn
Dec 31, 2025 73.03 Mn
Sep 30, 2025 -28.25 Mn
Jun 30, 2025 53.26 Mn
Mar 31, 2025 2.85 Mn
Dec 31, 2024 25.01 Mn
Sep 30, 2024 -81.05 Mn
Jun 30, 2024 36.52 Mn
Mar 31, 2024 -38.45 Mn
Dec 31, 2023 2.05 Mn
Sep 30, 2023 963,000.00
Jun 30, 2023 50.15 Mn
Mar 31, 2023 -30.15 Mn
Dec 31, 2022 3.11 Mn
Sep 30, 2022 33.23 Mn
Jun 30, 2022 12.61 Mn
Mar 31, 2022 -33.41 Mn
Dec 31, 2021 -4.03 Mn
Sep 30, 2021 68.18 Mn